You are here ยป News


February 16, 2018

Lausanne – 16 February 2018 – Galderma, a global leader focused on medical solutions in skin health, announced that a joint research agreement on Atopic Dermatitis (AD) has been signed with two leading academic institutions – Icahn School of Medicine at Mount Sinai in New York City, and Northwestern University Feinberg School of Medicine in Chicago. This seven-year collaborative agreement aims to enhance the scientific understanding of the underlying mechanisms driving atopic dermatitis in order to pave the way for developing better health care solutions to improve the quality of life of patients with the disease.

Atopic dermatitis is a complex multi-factorial and chronic inflammatory skin disease presenting with inflammatory skin lesions and itch. It is the most frequent form of eczema and is frequently associated with other allergic diseases such as asthma, hay fever and food allergies. It is most prevalent in children but can occur at any age.  Around the world, from 10 to 25 percent of children have atopic dermatitis. Ninety percent of those children develop the disease before their fifth birthday (1). Many children will continue to live with atopic dermatitis during adulthood, while others develop the disease as adults.

"While there are many exciting novel treatments moving into atopic dermatitis, these are based on increasing knowledge of pathogenic disease mechanisms in adults. However, we recently learned that atopic dermatitis disease initiation in children shows a different phenotype than that of adults with many years of chronic disease activity. In order to be able to better advance treatments into children, we must understand what are the factors that influence the progression of AD from children to adults. We are looking forward to studying molecular and cellular mechanisms underlying this progression, said Emma Guttman-Yassky, MD, PhD, Professor and Vice-Chair, Department of Dermatology, Icahn School of Medicine at Mount Sinai.

We have recently learned much about the cause of atopic dermatitis, which is driving new therapies. But all of this understanding is based on studies of adults; our recent studies have suggested that the immune and skin barrier changes in early atopic dermatitis in infants and young children are different from those in adults. We are looking forward to further dissecting the skin immune system as children age in both normal infants and children and in atopic dermatitis,,” said Amy Paller, MS, MD, Walter J Hamlin Professor and Chair of Dermatology at Northwestern University Feinberg School of Medicine and a physician at the Ann and Robert H. Lurie Children’s Hospital of Chicago.

There are still many unknowns in the pathogenic pathways driving atopic dermatitis. It is not known why the disease persists in some pediatric patients but clears in others before they reach adulthood. It is of critical importance to understand age-specific alterations in skin immunity and the epidermal barrier that promote disease onset, persistence, or clearance of atopic dermatitis, especially in children where the disease often starts.  Researchers from these collaborating institutions will work to shed light on the development and the course of pediatric atopic dermatitis through this long term longitudinal study.

The research grant represents one of the largest financial contributions provided by a single biopharmaceutical company in recent years dedicated for pure academic research and discovery in dermatology. ‘’This is clearly a strategic agreement for Galderma, and it confirms our longstanding commitment to the field of dermatology. With improved understanding on underlying mechanisms, we can better focus our efforts to develop more effective health care solutions for atopic dermatitis patients,” said Laurent Hennequin, PhD, Galderma Research Director.

Atopic dermatitis is one of Galderma’s key therapeutic areas of research and innovation. In 2016, Galderma entered into a global license agreement with Chugai Pharmaceutical Co., Ltd. for nemolizumab, an anti-IL-31 receptor A monoclonal antibody, which is currently under development for atopic dermatitis. Nemolizumab demonstrated its efficacy and safety in the treatment of atopic dermatitis in the first phase 2 study published in March 2017 in the New England Journal of Medicine2, showing a rapid and significant improvement of pruritus in patients with moderate-to-severe AD, as well as improvements in skin inflammation and several other symptoms.



About Galderma

Galderma, Nestlé Skin Health’s medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails. For more information, please visit



About Northwestern University Feinberg School of Medicine

Northwestern University Feinberg School of Medicine is a top 20 medical school where nationally recognized researchers collaborate with skilled clinicians to improve human health. More than 3,400 faculty members teach, practice medicine, and conduct research at the medical school, which is a central component of Northwestern Medicine, a premier academic health system. During the 2015-2016 academic year, Feinberg served 638 medical students, 879 PhD students and research fellows, 647 master’s and professional program students, and 1,135 residents and fellows. Last year, Feinberg scientists received $402.7 million in funding for research awards.


About the Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest integrated delivery system encompassing seven hospital campuses, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai’s vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The System includes approximately 7,100 primary and specialty care physicians; 10 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report’s “Honor Roll” of top U.S. hospitals; it is one of the nation’s top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in four other specialties in the 2017-2018 “Best Hospitals” issue. Mount Sinai’s Kravis Children’s Hospital also is ranked in six out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology and 50th for Ear, Nose, and Throat, while Mount Sinai Beth Israel, Mount Sinai St. Luke’s and Mount Sinai West are ranked regionally. For more information, visit, or find Mount Sinai on Facebook, Twitter and YouTube.



(1) American Academy of Dermatology (

(2) T. Ruzicka et al., Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis, N Engl J Med 2017; 376:826-35  


Media Contact

Sébastien Cros, Head of Corporate Communications,

Posted in: Press release

Follow us Follow us on twitter Follow us on Linkedin

Corporate responsibility

Growing a responsible dermatological community

Discover some of the positive initiatives we are involved in across the world



We are committed

See all videos